Skip to main content
SpringerLink
Log in

Circulatory miR-628-5p is downregulated in prostate cancer patients

  • Research Article
  • Published:
Tumor Biology

Abstract

Prostate cancer (PCa) is a major health concern for men in the USA. Aberrant expression of microRNAs (miRNAs) has been associated with the pathogenesis of various cancers, including PCa. Circulatory forms of miRNAs have been detected in serum and hold promise as minimally invasive cancer biomarkers. This study aimed to identify potential circulatory miRNAs that can provide insights into new mechanisms for clinical diagnosis of PCa and can serve as potential biomarkers and/or therapeutic targets. Candidate serum miRNAs were detected by using PCR microarray in a learning set of six African American (AA) and six Caucasian American (CA) PCa patients. Discriminating performance of candidate miRNAs was validated by qRT-PCR in serum samples from 36 AA (24 PCa patients and 12 controls) and 36 CA (16 PCa patients and 20 controls). From the miRNA profiling experiments, three differentially expressed miRNAs (miR-25, miR-101, and miR-628-5p) were selected for future validation. In the validation set, there was an overall low expression of miR-25 (p < 0.01), miR-101 (p < 0.001), and miR-628-5p (p < 0.0001) in serum of PCa patients as compared with normal individuals. Subdivision on the basis of ethnicity showed that serum expression levels of miR-628-5p were significantly downregulated in both AA and CA PCa patients when compared with their respective controls. Our results demonstrate that the three miRNAs, particularly miR-628-5p, may be further developed as a biomarker, which can serve as novel noninvasive biomarker for PCa diagnosis and prognosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11–30.

    Article  PubMed  Google Scholar 

  2. Yaman Agaoglu F, Kovancilar M, Dizdar Y, Darendeliler E, Holdenrieder S, Dalay N, et al. Investigation of mir-21, mir-141, and mir-221 in blood circulation of patients with prostate cancer. Tumor Biol. 2011;32:583–8.

    Article  CAS  Google Scholar 

  3. Roberts WW, Bergstralh EJ, Blute ML, Slezak JM, Carducci M, Han M, et al. Contemporary identification of patients at high risk of early prostate cancer recurrence after radical retropubic prostatectomy. Urology. 2001;57:1033–7.

    Article  CAS  PubMed  Google Scholar 

  4. Shariat SF, Semjonow A, Lilja H, Savage C, Vickers AJ, Bjartell A. Tumor markers in prostate cancer I: blood-based markers. Acta Oncol (Formerly: Acta Radiol Oncol). 2011;50:61.

    Article  Google Scholar 

  5. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281–97.

    Article  CAS  PubMed  Google Scholar 

  6. Friedman RC, Farh KK-H, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 2009;19:92–105.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Ferracin M, Veronese A, Negrini M. Micromarkers: miRNAs in cancer diagnosis and prognosis. Expert Rev Mol Diagn. 2010;10:297–308.

    Article  CAS  PubMed  Google Scholar 

  8. Kroh EM, Parkin RK, Mitchell PS, Tewari M. Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR). Methods. 2010;50:298–301.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 2001;25:402–8.

    Article  CAS  PubMed  Google Scholar 

  10. Wettenhall JM, Smyth GK. Limmagui: a graphical user interface for linear modeling of microarray data. Bioinformatics. 2004;20:3705–6.

    Article  CAS  PubMed  Google Scholar 

  11. Verhoeven KJF, Simonsen KL, McIntyre LM. Implementing false discovery rate control: increasing your power. Oikos. 2005;108:643–7.

    Article  Google Scholar 

  12. Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem. 2009;55:611–22.

    Article  CAS  PubMed  Google Scholar 

  13. Esposito F, Tornincasa M, Pallante P, Federico A, Borbone E, Pierantoni GM, et al. Down-regulation of the miR-25 and miR-30d contributes to the development of anaplastic thyroid carcinoma targeting the polycomb protein EZH2. J Clin Endocrinol Metab. 2012;97:E710–8.

    Article  CAS  PubMed  Google Scholar 

  14. Wang HJ, Ruan HJ, He XJ, Ma YY, Jiang XT, Xia YJ, et al. MicroRNA-101 is down-regulated in gastric cancer and involved in cell migration and invasion. Eur J Cancer. 2010;46:2295–303.

    Article  CAS  PubMed  Google Scholar 

  15. Watson JA, Bryan K, Williams R, Popov S, Vujanic G, Coulomb A, et al. miRNA profiles as a predictor of chemoresponsiveness in Wilms’ tumor blastema. PLoS One. 2013;8:e53417.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Poliseno L, Salmena L, Riccardi L, Fornari A, Song MS, Hobbs RM, et al. Identification of the miR-106b∼25 microRNA cluster as a proto-oncogenic PTEN-targeting intron that cooperates with its host gene MCM7 in transformation. Sci Signal. 2010;3:ra29.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Li LM, Hu ZB, Zhou ZX, Chen X, Liu FY, Zhang JF, et al. Serum microRNA profiles serve as novel biomarkers for HBV infection and diagnosis of HBV-positive hepatocarcinoma. Cancer Res. 2010;70:9798–807.

    Article  CAS  PubMed  Google Scholar 

  18. Li BS, Zhao YL, Guo G, Li W, Zhu ED, Luo X, et al. Plasma microRNAs, miR-223, miR-21 and miR-218, as novel potential biomarkers for gastric cancer detection. PLoS One. 2012;7:e41629.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Wu Q, Wang C, Lu Z, Guo L, Ge Q. Analysis of serum genome-wide microRNAs for breast cancer detection. Clin Chim Acta. 2012;413:1058–65.

    Article  CAS  PubMed  Google Scholar 

  20. Hu Z, Dong J, Wang LE, Ma H, Liu J, Zhao Y, et al. Serum microRNA profiling and breast cancer risk: the use of mir-484/191 as endogenous controls. Carcinogenesis. 2012;33:828–34.

    Article  CAS  PubMed  Google Scholar 

  21. Li X, Zhang Y, Zhang H, Liu X, Gong T, Li M, et al. miRNA-223 promotes gastric cancer invasion and metastasis by targeting tumor suppressor EPB41L3. Mol Cancer Res. 2011;9:824–33.

    Article  CAS  PubMed  Google Scholar 

  22. Kim BH, Hong SW, Kim A, Choi SH, Yoon SO. Prognostic implications for high expression of oncogenic microRNAs in advanced gastric carcinoma. J Surg Oncol. 2013;107:505–10.

    Article  CAS  PubMed  Google Scholar 

  23. Zhu L, Yan W, Rodriguez-Canales J, Rosenberg AM, Hu N, Goldstein AM, et al. MicroRNA analysis of microdissected normal squamous esophageal epithelium and tumor cells. Am J Cancer Res. 2011;1:574–84.

    PubMed  PubMed Central  Google Scholar 

  24. Fang W-K, Liao L-D, Li L-Y, Xie Y-M, Xu X-E, Zhao W-J, et al. Down-regulated desmocollin-2 promotes cell aggressiveness through redistributing adherens junctions and activating beta-catenin signalling in oesophageal squamous cell carcinoma. J Pathol. 2013;231:257–70.

    Article  CAS  PubMed  Google Scholar 

  25. Li Y, Tan W, Neo TW, Aung MO, Wasser S, Lim SG, et al. Role of the miR-106b-25 microRNA cluster in hepatocellular carcinoma. Cancer Sci. 2009;100:1234–42.

    Article  CAS  PubMed  Google Scholar 

  26. Dacic S, Kelly L, Shuai Y, Nikiforova MN. miRNA expression profiling of lung adenocarcinomas: correlation with mutational status. Mod Pathol. 2010;23:1577–82.

    Article  CAS  PubMed  Google Scholar 

  27. Razumilava N, Bronk SF, Smoot RL, Fingas CD, Werneburg NW, Roberts LR, et al. miR-25 targets TNF-related apoptosis inducing ligand (TRAIL) death receptor-4 and promotes apoptosis resistance in cholangiocarcinoma. Hepatology. 2012;55:465–75.

    Article  CAS  PubMed  Google Scholar 

  28. Zhang H, Zuo Z, Lu X, Wang L, Wang H, Zhu Z. MiR-25 regulates apoptosis by targeting Bim in human ovarian cancer. Oncol Rep. 2012;27:594–8.

    CAS  PubMed  Google Scholar 

  29. Varambally S, Cao Q, Mani RS, Shankar S, Wang X, Ateeq B, et al. Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science. 2008;322:1695–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Pang Y, Young CY, Yuan H. MicroRNAs and prostate cancer. Acta Biochim Biophys Sin (Shanghai). 2010;42:363–9.

    Article  CAS  Google Scholar 

  31. Ren G, Baritaki S, Marathe H, Feng J, Park S, Beach S, et al. Polycomb protein EZH2 regulates tumor invasion via the transcriptional repression of the metastasis suppressor RKIP in breast and prostate cancer. Cancer Res. 2012;72:3091–104.

    Article  CAS  PubMed  Google Scholar 

  32. Hao Y, Gu X, Zhao Y, Greene S, Sha W, Smoot DT, et al. Enforced expression of miR-101 inhibits prostate cancer cell growth by modulating the COX-2 pathway in vivo. Cancer Prev Res (Phila). 2011;4:1073–83.

    Article  CAS  Google Scholar 

  33. Alajez NM, Lenarduzzi M, Ito E, Hui AB, Shi W, Bruce J, et al. MiR-218 suppresses nasopharyngeal cancer progression through downregulation of survivin and the SLIT2-ROBO1 pathway. Cancer Res. 2011;71:2381–91.

    Article  CAS  PubMed  Google Scholar 

  34. Cao P, Deng Z, Wan M, Huang W, Cramer SD, Xu J, et al. MicroRNA-101 negatively regulates EZH2 and its expression is modulated by androgen receptor and HIF-1alpha/HIF-1beta. Mol Cancer. 2010;9:108.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Strillacci A, Griffoni C, Sansone P, Paterini P, Piazzi G, Lazzarini G, et al. MiR-101 downregulation is involved in cyclooxygenase-2 overexpression in human colon cancer cells. Exp Cell Res. 2009;315:1439–47.

    Article  CAS  PubMed  Google Scholar 

  36. Buechner J, Tomte E, Haug BH, Henriksen JR, Lokke C, Flaegstad T, et al. Tumour-suppressor microRNAs let-7 and miR-101 target the proto-oncogene MYCN and inhibit cell proliferation in MYCN-amplified neuroblastoma. Br J Cancer. 2011;105:296–303.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Carvalho J, van Grieken NC, Pereira PM, Sousa S, Tijssen M, Buffart TE, et al. Lack of microRNA-101 causes E-cadherin functional deregulation through EZH2 up-regulation in intestinal gastric cancer. J Pathol. 2012;228:31–44.

    CAS  PubMed  Google Scholar 

  38. Smits M, Mir SE, Nilsson RJ, van der Stoop PM, Niers JM, Marquez VE, et al. Down-regulation of miR-101 in endothelial cells promotes blood vessel formation through reduced repression of EZH2. PLoS One. 2011;6:e16282.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Zhang JG, Guo JF, Liu DL, Liu Q, Wang JJ. MicroRNA-101 exerts tumor-suppressive functions in non-small cell lung cancer through directly targeting enhancer of zeste homolog 2. J Thorac Oncol. 2011;6:671–8.

    Article  PubMed  Google Scholar 

  40. Sakurai T, Bilim VN, Ugolkov AV, Yuuki K, Tsukigi M, Motoyama T, et al. The enhancer of zeste homolog 2 (EZH2), a potential therapeutic target, is regulated by miR-101 in renal cancer cells. Biochem Biophys Res Commun. 2012;422:607–14.

    Article  CAS  PubMed  Google Scholar 

  41. Su H, Yang JR, Xu T, Huang J, Xu L, Yuan Y, et al. MicroRNA-101, down-regulated in hepatocellular carcinoma, promotes apoptosis and suppresses tumorigenicity. Cancer Res. 2009;69:1135–42.

    Article  CAS  PubMed  Google Scholar 

  42. Frankel LB, Wen J, Lees M, Hoyer-Hansen M, Farkas T, Krogh A, et al. microRNA-101 is a potent inhibitor of autophagy. EMBO J. 2011;30:4628–41.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Xu Y, An Y, Wang Y, Zhang C, Zhang H, Huang C, et al. miR-101 inhibits autophagy and enhances cisplatin-induced apoptosis in hepatocellular carcinoma cells. Oncol Rep. 2013;29:2019–24.

    CAS  PubMed  Google Scholar 

  44. Liu X, Zou L, Zhu L, Zhang H, Du C, Li Z, et al. miRNA mediated up-regulation of cochaperone p23 acts as an anti-apoptotic factor in childhood acute lymphoblastic leukemia. Leuk Res. 2012;36:1098–104.

    Article  CAS  PubMed  Google Scholar 

  45. Strillacci A, Valerii MC, Sansone P, Caggiano C, Sgromo A, Vittori L, et al. Loss of miR-101 expression promotes Wnt/β-catenin signalling pathway activation and malignancy in colon cancer cells. J Pathol. 2013;229:379–89.

    Article  CAS  PubMed  Google Scholar 

  46. Favreau AJ, Sathyanarayana P. miR-590-5p, miR-219-5p, miR-15b and miR-628-5p are commonly regulated by IL-3, GM-CSF and G-CSF in acute myeloid leukemia. Leuk Res. 2012;36:334–41.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

We acknowledge the support of the Genomic and Epigenetic Shared Resource (GESR) and Biostatistics and Bioinformatics Shared Resource (BBSR) at the LCCC. Assistance by Ms. Sunghae Uhm is gratefully acknowledged. Funding support: NIH: CA162264 and CA141935; PCRP: PC111314.

Conflicts of interest

None

Author information

Authors and Affiliations

  1. Cancer Research Laboratory, Department of Biology, Chemistry and Physics, University of the District of Columbia, 4200 Connecticut Avenue, NW, Washington, DC, 20008, USA

    Anvesha Srivastava, Helle Goldberger, Alexander Dimtchev & Deepak Kumar

  2. Department of Biochemistry, Victor Babes University of Medicine and Pharmacy Timisoara, Timisoara, Romania

    Catalin Marian

  3. Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, 20057, USA

    Offie Soldin, Xin Li, Sean P. Collins, Simeng Suy & Deepak Kumar

Authors
  1. Anvesha Srivastava
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Helle Goldberger
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Alexander Dimtchev
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Catalin Marian
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Offie Soldin
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Xin Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Sean P. Collins
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Simeng Suy
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Deepak Kumar
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Deepak Kumar.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Srivastava, A., Goldberger, H., Dimtchev, A. et al. Circulatory miR-628-5p is downregulated in prostate cancer patients. Tumor Biol. 35, 4867–4873 (2014). https://doi.org/10.1007/s13277-014-1638-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-014-1638-1

Keywords

Search

Navigation